PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
35014217-0	2022	A Phase 1 study of GDC-0134, a dual leucine zipper kinase inhibitor, in ALS.	UNII-4N6KQ7D685	19-27	mitogen-activated protein kinase kinase kinase 12	Homo sapiens	31-57
35014217-2	2022	This first-in-human study investigated safety, tolerability, and pharmacokinetics (PK) of oral GDC-0134, a small-molecule DLK inhibitor.	UNII-4N6KQ7D685	95-103	mitogen-activated protein kinase kinase kinase 12	Homo sapiens	122-125
35014217-9	2022	Patients showed GDC-0134 exposure-dependent plasma NFL elevations; DLK cKO mice also exhibited plasma NFL compared to wild-type littermates.	UNII-4N6KQ7D685	16-24	neurofilament light chain	Homo sapiens	51-54
35014217-11	2022	NFL elevations in GDC-0134-treated patients and DLK cKO mice raised questions about interpretation of biomarkers affected by both disease and on-target drug effects.	UNII-4N6KQ7D685	18-26	neurofilament light chain	Homo sapiens	0-3